Puma Biotechnology Q4 2023 Adj EPS $0.310 Beats $0.300 Estimate, Sales $72.200M Miss $73.550M Estimate
Portfolio Pulse from Benzinga Newsdesk
Puma Biotechnology (NASDAQ:PBYI) reported Q4 2023 earnings of $0.310 per share, exceeding the $0.300 estimate, but missed sales estimates with $72.200M against the expected $73.550M. This represents a 9.89% increase in sales compared to the same period last year.
February 29, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Puma Biotechnology reported higher than expected Q4 2023 earnings per share but missed on sales estimates, with a year-over-year sales increase of 9.89%.
While Puma Biotechnology exceeded EPS estimates, the slight miss on sales forecasts could temper investor enthusiasm, leading to a neutral short-term impact on the stock price. The year-over-year sales growth is positive, indicating underlying business strength, but the miss on expectations may lead to mixed reactions in the market.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100